Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

home / authors / matthew-davids-md-mmsc-dana-farber-cancer-institute

Articles

Matthew S. Davids, MD, MMSc

Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
January 24th 2024

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Read More

Expert on Leukemia

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
February 14th 2022

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Read More

Expert on Leukemia

ASH 2021: Key Data in Chronic Myeloid Leukemia

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
February 7th 2022

Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.

Read More

Expert on Leukemia

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
January 31st 2022

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.

Read More

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

Jennifer Woyach, MD, Ohio State University;Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Nathan H. Fowler, MD, MD Anderson Cancer Center;Sarah Rutherford, MD, Weill Cornell Medical College
January 22nd 2021

Read More

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

Jennifer Woyach, MD, Ohio State University;Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Nathan H. Fowler, MD, MD Anderson Cancer Center;Sarah Rutherford, MD, Weill Cornell Medical College
January 22nd 2021

Read More

ASH 2020 Updates in CLL

ASH 2020 Updates in CLL

Jennifer Woyach, MD, Ohio State University;Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Nathan H. Fowler, MD, MD Anderson Cancer Center;Sarah Rutherford, MD, Weill Cornell Medical College
January 22nd 2021

Read More

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
January 18th 2021

Read More

Rapid Readouts: Five-Year Analysis of MURANO Study

Rapid Readouts: Five-Year Analysis of MURANO Study

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
December 23rd 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need